Skip to Content
Merck
  • FBXL20 promotes breast cancer malignancy by inhibiting apoptosis through degradation of PUMA and BAX.

FBXL20 promotes breast cancer malignancy by inhibiting apoptosis through degradation of PUMA and BAX.

The Journal of biological chemistry (2021-09-30)
Rajesh Kumar Manne, Yashika Agrawal, Sunil K Malonia, Shahid Banday, Sarathkumar Edachery, Asha Patel, Avinash Kumar, Praveenkumar Shetty, Manas Kumar Santra
ABSTRACT

Apoptosis is a programmed cell death that efficiently removes damaged cells to maintain tissue homeostasis. Defect in apoptotic machinery can lead to tumor development, progression, and resistance to chemotherapy. PUMA (p53 upregulated modulator of apoptosis) and BAX (BCL2-associated X protein) are among the most well-known inducers of apoptosis. It has been reported that expression levels of BAX and PUMA are controlled at the posttranslational level by phosphorylation. However, the posttranslational regulation of these proapoptotic proteins remains largely unexplored. In this study, using biochemical, molecular biology, flow cytometric, and immunohistochemistry techniques, we show that PUMA and BAX are the direct target of the F-box protein FBXL20, which restricts their cellular levels. FBXL20 directs the proteasomal degradation of PUMA and BAX in a protein kinase AKT1-dependent manner to promote cancer cell proliferation and tumor growth. Interestingly, inactivation of AKT1 results in activation of another protein kinase GSK3α/β, which facilitates the proteasomal degradation of FBXL20 by another F-box protein, FBXO31. Thus, a switch between two signaling kinases AKT1 and GSK3α/β modulates the functional activity of these proapoptotic regulators, thereby determining cell survival or death. RNAi-mediated ablation of FBXL20 results in increased levels of PUMA as well as BAX, which further enhances the sensitivity of cancer cells to chemotherapeutic drugs. We showed that high level expression of FBXL20 in cancer cells reduces therapeutic drug-induced apoptosis and promotes chemoresistance. Overall, this study highlights the importance of targeting FBXL20 in cancers in conjunction with chemotherapy and may represent a promising anticancer strategy to overcome chemoresistance.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Phosphothreonine antibody, Mouse monoclonal, clone PTR-8, purified from hybridoma cell culture
Sigma-Aldrich
BAX, GST tagged human, recombinant, expressed in E. coli, ≥70% (SDS-PAGE), buffered aqueous glycerol solution
Sigma-Aldrich
(S)-(+)-Camptothecin, ≥90% (HPLC), powder
Sigma-Aldrich
Akt Inhibitor, The Akt Inhibitor controls the biological activity of Akt. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
Sigma-Aldrich
Monoclonal Anti-Phosphoserine antibody produced in mouse, clone PSR-45, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-α-Tubulin antibody produced in mouse, ascites fluid, clone B-5-1-2
Sigma-Aldrich
Akt1 active human, recombinant, expressed in baculovirus infected Sf9 cells, ≥75% (SDS-PAGE)
Sigma-Aldrich
MG-132, A cell-permeable, potent, reversible proteasome inhibitor (Ki = 4 nM).